Similar articles

• Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma.

  Lin JC, Wang WY, Chen KY, Wei YH, Liang WM, Jan JS, Jiang RS. Lin JC, et al. N Engl J Med. 2004 Jun 10;350(24):2461-70. doi: 10.1056/NEJMoa032260. N Engl J Med. 2004. PMID: 15190138
• [Prognostic impact of plasma Epstein-Barr virus DNA concentration on distant metastasis in nasopharyngeal carcinoma].

  Hou X, Zhang L, Zhao C, Li S, Lu LX, Han F, Shao JY, Huang PY. Hou X, et al. Ai Zheng. 2006 Jul;25(7):785-92. Ai Zheng. 2006. PMID: 16831265 Chinese.
• Metronomic adjuvant chemotherapy improves treatment outcome in nasopharyngeal carcinoma patients with postradiation persistently detectable plasma Epstein-Barr virus deoxyribonucleic acid.

  Twu CW, Wang WY, Chen CC, Liang KL, Jiang RS, Wu CT, Shih YT, Lin PJ, Liu YC, Lin JC. Twu CW, et al. Int J Radiat Oncol Biol Phys. 2014 May 1;89(1):21-9. doi: 10.1016/j.ijrobp.2014.01.052. Int J Radiat Oncol Biol Phys. 2014. PMID: 24725686
• Systemic treatment strategies and therapeutic monitoring for advanced nasopharyngeal carcinoma.

  Ma BB, Chan AT. Ma BB, et al. Expert Rev Anticancer Ther. 2006 Mar;6(3):383-94. doi: 10.1586/14737140.6.3.383. Expert Rev Anticancer Ther. 2006. PMID: 16503855 Review.
• Advances in nasopharyngeal carcinoma.

  Guigay J. Guigay J. Curr Opin Oncol. 2008 May;20(3):264-9. doi: 10.1097/CCO.0b013e3282fad846. Curr Opin Oncol. 2008. PMID: 18391624 Review.